Your shopping cart is currently empty

Bazedoxifene is a non-steroidal, orally active selective estrogen receptor modulator that exhibits activity against ERα and ERβ with IC50 values of 26 nM and 99 nM, respectively. Bazedoxifene also inhibits IL-6/GP130 protein interactions. Bazedoxifene is utilized in research on postmenopausal osteoporosis and pancreatic cancer, serving as a dual-purpose compound for hormonal and cytokine pathway investigations.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $35 | In Stock | In Stock | |
| 5 mg | $81 | In Stock | In Stock | |
| 10 mg | $123 | In Stock | In Stock | |
| 25 mg | $233 | In Stock | In Stock | |
| 50 mg | $318 | In Stock | In Stock | |
| 100 mg | $497 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $89 | In Stock | In Stock |
| Description | Bazedoxifene is a non-steroidal, orally active selective estrogen receptor modulator that exhibits activity against ERα and ERβ with IC50 values of 26 nM and 99 nM, respectively. Bazedoxifene also inhibits IL-6/GP130 protein interactions. Bazedoxifene is utilized in research on postmenopausal osteoporosis and pancreatic cancer, serving as a dual-purpose compound for hormonal and cytokine pathway investigations. |
| Targets&IC50 | ERα:26 nM, ERβ:99 nM |
| In vitro | In PANC-1, AsPC-1, and HPAF-II pancreatic carcinoma cells, Bazedoxifene (5-20μM, 2 hours) can inhibit IL-6 and IL-11-induced STAT3 phosphorylation in a dose-dependent manner [2]. |
| In vivo | In the Capan-1 and HPAF-II pancreatic carcinoma xenograft models in mice, Bazedoxifene (5mg/kg/d, administered continuously for 18 days) significantly inhibited tumor growth and induced tumor cell apoptosis. The effect was more pronounced when used in combination with chemotherapeutic agents [2]. |
| Synonyms | TSE-424, TSE424 |
| Molecular Weight | 470.61 |
| Formula | C30H34N2O3 |
| Cas No. | 198481-32-2 |
| Smiles | OC=1C=CC(=CC1)C2=C(C3=CC(O)=CC=C3N2CC4=CC=C(OCCN5CCCCCC5)C=C4)C |
| Relative Density. | 1.19g/cm3 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (169.99 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (7.01 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.